Studies with both agents at different concentrations showed synergistic results in ovarian cancer cell lines (OVCAR8, OVCAR3 and IGROV1), triple negative (HS‐578T, HCC3153 and MDA‐MB‐231), and the HER2‐positive BT474 (Figure 5B). The gene discussed is ERBB2; the disease is ovarian carcinoma.